MIRACLOX

This brand name is authorized in Nigeria.

Active ingredients

The drug MIRACLOX contains a combination of these active pharmaceutical ingredients (APIs):

1	Ampicillin trihydrate UNII 7C782967RD - AMPICILLIN
	Ampicillin is a broad spectrum penicillin, indicated for the treatment of a wide range of bacterial infections caused by ampicillin sensitive organisms.
	Read more about Ampicillin
2	Cloxacillin UNII 65LCB00B4Y - CLOXACILLIN SODIUM
	Cloxacillin is a semi-synthetic beta-lactamase resistant penicillin with activity against gram-negative and gram-positive bacteria including beta-lactamase producing staphylococci. Cloxacillin acts by interfering with the formation of new bacterial cell wall by dividing organisms.
	Read more about Cloxacillin

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
04-7004	Suspension	Miraclox Oral Suspension SUSP 125 mg/5 mL; 125 mg/5 mL 1 X 100ML	Miraclox Oral Suspension 04-7004 Miraclox AMPICILLIN, CLOXACILLIN ANTIBIOTICS AMPICILLIN 125MG, CLOXACILLIN 125MG/5ML SUSPENSION X 100ML PRESCRIPTION ONLY MEDICINE TREATMENT OF SUSCEPTIBLE BACTERIA INFECTIONS MIRAFLASH NIGERIA LIMITED NIGERIA MIRAFLASH NIGERIA LIMITED NIGERIA 09/29/2022 09/28/2027	29/09/2022
A11-0038	Capsule	Miraclox Capsules CAP 250 mg; 250 mg 10 X 10	Miraclox Capsules A11-0038 Miraclox AMPICILLIN, CLOXACILLIN ANTIBIOTICS AMPICILLIN 250MG, CLOXACILLIN 250MG CAPSULES 10 X 10 PRESCRIPTION ONLY MEDICINE TREATMENT OF SUSCEPTIBLE BACTERIA INFECTIONS MIRAFLASH NIGERIA LIMITED NIGERIA MIRAFLASH NIGERIA LIMITED NIGERIA 08/25/2022 08/24/2027	25/08/2022

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J01CA51	Ampicillin, combinations	J Antiinfectives for systemic use → J01 Antibacterials for systemic use → J01C Beta-lactam antibacterials, penicillins → J01CA Penicillins with extended spectrum
Discover more medicines within J01CA51

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	04-7004, A11-0038